Preventive effects of lignan extract from flax hulls on experimentally induced benign prostate hyperplasia.
Consumption of diet rich in lignans may decrease the risk of some chronic hormonal conditions such as benign prostatic hyperplasia (BPH). This study investigated whether a lignan-rich extract from flaxseed hulls, LinumLife EXTRA (LLE), could prevent BPH using the testosterone propionate (TP)-induced BPH rat model. Male Wistar-Unilever rats were randomly divided into four groups of 12 rats each: a negative control group fed with control diet and receiving daily subcutaneous injections of corn oil without TP, and three groups fed with control diet (positive control), diet containing 0.5% LLE (LLE 0.5) or 1.0% LLE (LLE 1.0) and receiving daily subcutaneous injections of TP in corn oil. Treatments with diets started 2 weeks before the induction of BPH and were carried out for 5 consecutive weeks. The influence of TP and LLE on body weight (BW), food and water consumptions, and enterolactone (ENL) levels in serum and urine of rats was examined at the end of the 5-week treatment period. TP significantly diminished the mean body weight gain (MBWG) of positive control rats and their food and water consumptions while LLE reduced significantly this MBWG reduction in a dose-dependent manner. The lignan-rich extract significantly inhibited TP-induced prostate size ratio (prostate weight/rat BW) increase in comparison with positive controls (P<.001). This effect was dose dependent. Higher serum and urine levels of ENL correlated well with the dose of extract provided to rats. It was concluded that the lignan-rich flaxseed hull extract prevented the TP-induced BPH indicating it might be beneficial in the prevention of BPH.
1 ETAP-Applied Ethology, Research Centre in Pharmacology , Cancerology & Human Pathologies, Toxicology and Nutrition-Health, Vandœuvre-lès-Nancy, France .
Jean-François
JF
Bisson
Sophie
S
Hidalgo
Rudy
R
Simons
Marian
M
Verbruggen
D015107:4-Butyrolactone / Q000031:analogs & derivatives / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use; D000818:Animals; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D004326:Drinking / Q000187:drug effects; D002149:Energy Intake / Q000187:drug effects; D019597:Flax / Q000737:chemistry*; D006965:Hyperplasia; D017705:Lignans / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use*; D008297:Male; D008517:Phytotherapy; D010936:Plant Extracts / Q000494:pharmacology / Q000627:therapeutic use*; D011467:Prostate / Q000187:drug effects* / Q000473:pathology; D011470:Prostatic Hyperplasia / Q000139:chemically induced / Q000517:prevention & control*; D017208:Rats, Wistar; D012639:Seeds / Q000737:chemistry; D043343:Testosterone Propionate; D015430:Weight Gain / Q000187:drug effects
D017705:Lignans; D010936:Plant Extracts; D015107:4-Butyrolactone; D043343:Testosterone Propionate; C029497:2,3-bis(3'-hydroxybenzyl)butyrolactone
SDG; benign prostate hyperplasia; enterolactone; flax; lignan-rich extract; preventive effect; rat